NCT06311760View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

February 20, 2025

Study Completion Date

February 20, 2025

Conditions
Healthy Participants Study
Interventions
DRUG

AZD0292

AZD0292 will be administered as single dose via IV infusion.

DRUG

Placebo

Placebo will be administered as IV infusion.

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY